Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD
Tan X, Harton J, Gutierrez C, Liang Y, Xie L, Muhammad C, Swift C, de Havenon A. Comparative effectiveness of OW GLP-1 RAs and other glucose-lowering therapies among Medicare beneficiaries with T2D and ASCVD. Diabetes Research And Clinical Practice 2025, 229: 112473. PMID: 40934962, DOI: 10.1016/j.diabres.2025.112473.Peer-Reviewed Original ResearchHealthcare resource utilizationAssociated with reduced riskMedicare beneficiariesAssociated with reduced risk of CV eventsGLP-1 RAsMedicare fee-for-service claims dataTotal medical visitsOW GLP-1 RAsTotal medical costsObservational cohort studyMedical visitsRisk of CV eventsClaims dataGuideline recommendationsIncidence rateCohort studyReal-world settingsMedicareMedical costsOnce-weeklyGLP-1Glucose-lowering therapyStudy findingsASCVDLow risk
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply